AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie International — Reported revenue growth YoY by Year
International — Reported revenue growth YoY (%) (%)
AbbVie International — Reported revenue growth YoY: 9.4% in FY2025, up 2.4 pts from a year earlier.
Latest, FY2025
9.4%
Period ended Dec 31, 2025
Change on a year earlier
+2.4 pts
7.0% in FY2024
History
4 years
Since FY2022
Sources
4
Documents cited below
Where the FY2025 figure comes from
“|| NET REVENUES | $ | 46,603 | $ | 14,557 | $ | 61,160 | 8.3% | 9.4% | 8.6% | 9.2% | 8.5%”
Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Reported in Form 8-K Key Product Revenues.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | International — Reported revenue growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9.4% | +2.4 pts | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | 7.0% | +6.2 pts | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | 0.8% | +3.5 pts | Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗ |
| FY2022 | Dec 31, 2022 | -2.7% | – | Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗ |
Cite this data
StockData. (2026). AbbVie International — Reported revenue growth YoY (%), annual FY2022–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/rev-total-intl-rep-yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.